[Gem Aromatics](gem aromatics) disclosed that its Managing Director & CEO, Yash Parekh, has increased his shareholding through an open market transaction executed on June 04, 2026. The acquisition involved the purchase of 85,000 equity shares, raising his total stake in the manufacturer and exporter of essential oils and aromatics chemicals to 9.54% of the paid-up share capital.

Following this transaction, Parekh's total shareholding stands at 4,988,157 equity shares, up from 4,903,157 shares or 9.38% prior to the purchase. The company's equity share capital is ₹10,44,74,276 divided into 5,22,37,138 equity shares of ₹2 each. The disclosure was submitted in compliance with Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015.

The filing, confirmed by Akshita Deepak Gohil, Company Secretary & Compliance Officer, stated that the transaction was conducted on the National Stock Exchange of India Limited (NSE). Parekh serves as a Key Managerial Personnel (KMP) and a designated person within the organization. The company noted that the value of the transaction excludes taxes, brokerage, and other applicable charges.

Transaction Details

The table below outlines the specifics of the share purchase by the designated person:

Gem Aromatics Limited reported a sequential recovery in its financial performance for the quarter ended March 31, 2026 (Q4FY26), driven by improved volumes and price realization. The company released the transcript of its earnings conference call held on May 22, 2026, detailing the operational and financial highlights for the quarter and full year.

Financial Performance

Revenue from operations for the quarter stood at INR112 crores on a stand-alone basis, compared to INR84 crores in Q3FY26, registering a sequential growth of 34%. Consolidated revenue stood at INR110 crores as compared to INR79 crores in the previous quarter, reflecting a sequential growth of 40%. This improvement was supported by better traction across non-mint products, particularly clove and its derivatives.

Gross profit margins improved sequentially to 23.4% on a stand-alone basis and 30.5% on a consolidated basis. EBITDA margins improved to 13.4% on a standalone basis and 14.2% on a consolidated basis. The company reported a consolidated PAT of INR1 crore compared to a loss of INR5 crores in the previous quarter.

Operational Highlights

Management attributed the recovery to better clarity on U.S.A. tariffs and improving trade conditions. A key highlight was the progress at the Dahej greenfield facility under Krystal Ingredients Private Limited, where commercial production of Gemcool 5 and Safranal commenced on February 26, 2026. The company successfully completed a key global quality and compliance audit for the facility.

However, profitability was impacted by higher depreciation following the capitalization of a substantial portion of capex for the Dahej project. Out of the total planned capex of approximately INR270 crores, nearly INR260 crores has been incurred and capitalized. The plant remains production-ready for phenol-based derivatives, but production timelines have been impacted due to elevated raw material prices and availability issues caused by geopolitical developments.

Outlook

Looking ahead, the company provided guidance for FY28, targeting a consolidated turnover of INR1,100 crores and EBITDA margins in the range of 16% to 18%. Management stated that FY27 guidance would be provided later, citing geopolitical uncertainties and the need to monitor the ramp-up of the new facility. The focus remains on improving utilization levels, operational efficiencies, and product mix optimization.